| Entry |
|
|---|
| Name |
Dolutegravir sodium and rilpivirine hydrochloride;
Juluca (TN) |
|---|
| Product |
|
|---|
| Component |
Dolutegravir sodium [DR: D10113], Rilpivirine hydrochloride [DR: D09958]
|
|---|
| Remark |
| Therapeutic category: | 6250 |
|
|---|
| Efficacy |
Antiviral |
|---|
| Disease |
|
|---|
| Comment |
Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A; it is also an inhibitor of OCT2 and MATE1.
Rilpivirine is primarily metabolized by CYP3A.
|
|---|
| Target |
HIV-1 integrase
RNA-directed DNA polymerase |
|---|
| Metabolism |
|
|---|
| Interaction |
Transporter inhibition: SLC22A2 [HSA: 6582], SLC47A1 [hsa: 55244]
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AR Antivirals for treatment of HIV infections, combinations
J05AR21 Dolutegravir and rilpivirine
D11282 Dolutegravir sodium and rilpivirine hydrochloride <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Combinations
Dolutegravir/ Rilpivirine
D11282 Dolutegravir sodium and rilpivirine hydrochloride
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D11282 Dolutegravir sodium and rilpivirine hydrochloride
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11282
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11282
Drug transporters
D11282
|
|---|
| Other DBs |
|
|---|
